Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 901–1,000 of 1,000
The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy
Gudd, C. L. C., & Possamai, L. A. (2022) · Cancers · doi:10.3390/cancers14081913 · Cited by 20
Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function
Hawley, K. M., Eclov, R. J., Schnorenberg, M. R., Tian, Y. P., Shah, R. N., Thomas-Toth, A. T., Fefferman, M. L., Bird, G. H., Walensky, L. D., Tirrell, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209044119 · Cited by 19
Liu, M., Wang, X., Du, X., Wu, W., Zhang, Y., Zhang, P., Ai, C., Devenport, M., Su, J., Muthana, M. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5663 · Cited by 22
Zhang, F., Zheng, Z., Wang, L., Zeng, W., Wei, W., Zhang, C., Zhao, Z., & Liang, W. P. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01641-4 · Cited by 21
Mukherjee, D., Romano, E., Walshaw, R. C., Zeef, L. A. H., Banyard, A., Kitcatt, S. J., Cheadle, E. J., Tuomela, K., Pendharkar, S., Al-Deka, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2223094 · Cited by 21
Schoenfeld, D. A., Djureinovic, D., Su, D. G., Zhang, L., Lu, B. Y., Kamga, L., Mann, J. E., Huck, J. D., Hurwitz, M. E., Braun, D. A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.184545 · Cited by 22
“Similar analyses of other neighborhood groups revealed deenrichment of Tregs (group #1) and mild enrichment of an activated CD4 + T cell population (group #5) (Supplemental Figure 6, C–”
InfluentialRodríguez-Barbosa, J.-I., Fernández‐Renedo, C., Bravo, A., Bühler, L. H., & del Rio, M. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.101 · Cited by 21
Song, J., Huang, H.-H., Zhang, C., Yang, H.-G., Zhang, J., Xu, R., Jin, L., Shi, M., Wang, F., & Jiao, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02465 · Cited by 19
“Anti-CTLA-4 antibodies have been shown to deplete Tregs (33).”
BackgroundShamseddine, A. I., Zeidan, Y. H., Kreidieh, M., Khalifeh, I. M., Turfa, R., Kattan, J. G., Mukherji, D., Temraz, S. N., Alqasem, K. S., Amarin, R., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07333-y · Cited by 20
“Of note, while radiation therapy-induced immunogenic cell death occurs within 1–3 days in breast tumor cells, anti-tumor immunity to melanoma is improved when anti-CTLA-4 antibody precedes radiation therapy [52, 58, 59].”
Song, D., Liu, X., Dong, C., Wang, Q., Sha, C., Liu, C., Ning, Z., Han, J., Liu, H., Zong, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02449-y · Cited by 19
Targeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 20
Pinard, C. J., Lagree, A., Lu, F., Klein, J., Oblak, M. L., Salgado, R., Pinto‐Cardenas, J. C., Brunetti, B., Muscatello, L. V., Sarli, G., et al. (2022) · Cancers · doi:10.3390/cancers14205008 · Cited by 23
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells
Sun, M. T., Ha, N., Pham, D.-H., Frederick, M. A., Sharma, B., Naruse, C., Asano, M., Pipkin, M. E., George, R. E., & Thai, T. (2017) · Scientific Reports · doi:10.1038/srep42888 · Cited by 20
Kong, B. Y., Bolton, H. A., Kim, J. W., Silveira, P. A., Fromm, P. D., & Clark, G. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00050 · Cited by 22
“Anti-CTLA-4mAbs mediate Fc-receptor dependent depletion of Tregs in mice (83) but not in humans treated with anti-CTLA-4 mAbs (38).”
BackgroundReprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Cancer Immunotherapy and the Nectin Family
Johnston, R. J., Lee, P. S., Strop, P., & Smyth, M. J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060920-084910 · Cited by 21
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
Gao, H. J., Cai, H., Liu, J., Wang, X., Zheng, P., Devenport, M., Xu, T., Dou, F., Liu, Y., & Zhou, A. (2020) · Cell Discovery · doi:10.1038/s41421-020-00202-9 · Cited by 19
Khanolkar, R. C., Zhang, C., Al-Fatyan, F., Lawson, L., Depasquale, I., Meredith, F. M., Muller, F., Nicolson, M. C., Dahal, L. N., Eid, R. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763877 · Cited by 20
“Anti-CTLA-4 antibodies may also function by directly binding to and depleting Treg via macrophage dependent antibodydependent cell-mediated cytotoxicity (ADCC) within the tumor microenvironment (21, 22).”
BackgroundEngineering antibodies for conditional activity in the solid tumor microenvironment
Liu, Y., Nguyen, A. W., & Maynard, J. A. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102809 · Cited by 19
Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45625-0 · Cited by 19
Enhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18
Ward, F. J., Dahal, L. N., & Eid, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02182 · Cited by 19
“mediated depletion of the Treg through antibody-dependent cellmediated cytotoxicity (ADCC) within the tumor environment or at the infusion site (63).”
BackgroundFlies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 19
“The complex interactions involving CTLA-4 are further complicated by some anti-CTLA-4 monoclonal antibody effects that are mediated through Fc receptor signaling (11, 101, 102).”
BackgroundYe, S., Fox, M., Belmar, N. A., Sho, M., Chao, D. T., Choi, D., Fang, Y., Zhao, V., Keller, S. F., Starling, G. C., et al. (2017) · Journal of Immunology Research · doi:10.1155/2017/5737159 · Cited by 18
“In an immune-competent environment, there are studies showed that macrophage plays an important role in depleting target cells [33, 34] as well as in mediating antitumor immunity [35].”
Sun, N.-Y., Chen, Y., Lin, H.-W., Chiang, Y., Chang, C.-F., Tai, Y., Chen, C., Sun, W., Chien, C. L., & Cheng, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.039 · Cited by 18
Double immune checkpoint blockade in advanced NSCLC
Mariniello, A., Novello, S., Scagliotti, G. V., & Ramalingam, S. S. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102980 · Cited by 19
CD36 — the Achilles’ heel of Treg cells
Horton, B. L., & Spranger, S. (2020) · Nature Immunology · doi:10.1038/s41590-020-0601-0 · Cited by 18
Perazella, M. A., & Sprangers, B. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab052 · Cited by 17
“Whereas ICIs were originally believed to act solely in an antagonistic manner, more recent data suggest that ICIs also give rise to cytotoxic reactions [1] and depletion of intratumoral regulatory T cells [2].”
ResultAttias, M., & Piccirillo, C. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 20
“Indeed, in preclinical models, Fc γ RIV + TAMs, but not natural killer (NK) cells, induce T reg TIL depletion upon engagement of murine anti-CTLA-4 mAbs (Simpson et al., 2013).”
Single cell suppression profiling of human regulatory T cells
Søndergaard, J. N., Tulyeu, J., Priest, D., Sakaguchi, S., & Wing, J. B. (2025) · Nature Communications · doi:10.1038/s41467-024-55746-1 · Cited by 18
“16.”
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Akbay, E. A., & Kim, J. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.04 · Cited by 17
Sow, H. S., Benonisson, H., Breukel, C., Visser, R., Verhagen, O. J. H. M., Bentlage, A. E. H., Brouwers, C. M., Claassens, J. W. C., Linssen, M. M. L., Camps, M. G. M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31899 · Cited by 18
“Preferential reduction of this myeloid subset by anti-PD-L1 mIgG2a may be due to its high levels of surface PD-L1 expression compared to other immune and nonimmune cells, similar to that proposed for anti-CTLA4 mAb, which preferentially depletes high CTLA4 expressing regulatory T cells.(12) As mIgG2a (but not IgG1) ca…”
BackgroundGARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment
Bouchard, A., Collin, B., Garrido, C., Bellaye, P., & Kohli, É. (2021) · Biology · doi:10.3390/biology10090836 · Cited by 18
“These anti-GARP antibodies, blocking the GARP-TGF-β interaction, could have advantage in cancer by transiently inhibiting the immunosuppressive function of Tregs without physically eliminating them, as this is the case for CTLA-4 antibodies [74,75].”
Regulatory T cells as therapeutic targets and mediators
Sharma, A., & Rudra, D. (2019) · International Reviews of Immunology · doi:10.1080/08830185.2019.1621310 · Cited by 18
“Recent preclinical studies demonstrated that anti-CTLA-4 antibody isotypes especially IgG2a deplete Tregs in mouse tumor models [145,146].”
BackgroundImmunometabolism of regulatory T cells in cancer
Galgani, M., Bruzzaniti, S., Rocca, C. L., Micillo, T., de Candia, P., Bifulco, M., & Matarese, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100936 · Cited by 17
Laengle, J., Kuehrer, I., Kulu, A., Kabiljo, J., Ammon, D., Zirnbauer, R., Stift, A., Herbst, F., Dauser, B., Monschein, M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.27769 · Cited by 16
Cheng, H., Li, S., Liu, H., Yan, M., Wang, J., Huang, J., Liu, S., Yang, Y., Cao, X., Cui, P., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02140-2 · Cited by 16
“To exclude potential confounders linked to T reg depletion 24 , we performed additional flow cytometry (FCM) analysis of lung T reg cell populations.”
Turning up the heat: CTLA4 blockade in urothelial cancer
Stockem, C. F., Galsky, M. D., & van der Heijden, M. S. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00801-7 · Cited by 17
“Results of several preclinical studies revealed a decrease in T reg cell numbers after CTLA4 blockade 67,69,73–76 .”
Smith, F. D., Pierce, R. H., Thisted, T., & van der Horst, E. H. (2023) · Antibodies · doi:10.3390/antib12030055 · Cited by 16
“Recent data demonstrate that Fc γR-mediated antibody-dependent cellular cytotoxicity (ADCC) is a critical, and perhaps dominant, mechanism underlying anti-CTLA-4 activity in the tumor microenvironment [31,32].”
BackgroundBond, A., Fiaz, S., Rollins, K., Nario, J. E. Q., Snyder, E., Atkins, D. J., Rosen, S. J., Granados, A., Dey, S. S., Wilson, M. Z., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.07.017 · Cited by 16
“9,46 Some therapies, like the anti-CD20 antibody rituximab, heavily rely on ADCP as a mechanism for eliminating cancer cells.”
Immunotherapeutic Strategies in Non-Small-Cell Lung Cancer: The Present and the Future
Steendam, C. M. J., Dammeijer, F. F., Aerts, J. G. J. V., & Cornelissen, R. (2017) · Immunotherapy · doi:10.2217/imt-2016-0151 · Cited by 18
Current Strategies to Enhance Anti-Tumour Immunity
Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 21
“Anti-CTLA-4 antibodies have also been shown to broaden the immune response as well as deplete tumour resident regulatory T-cells (Tregs) [121,122].”
BackgroundA T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
Philip, H., Snir, T., Gordin, M., Shugay, M., Zilberberg, A., & Efroni, S. (2021) · iScience · doi:10.1016/j.isci.2021.102100 · Cited by 17
“As is known for the specific anti-CTLA-4 antibody clone we used (9H10), all mice responded to treatment (see also Simpson et al., 2013).”
MethodZhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 17
“This depletion effect, dependent on local microenviron-mental features, significantly attenuates Treg-mediated suppression of effector T cells [107].”
Guo, Q., Zhang, X., Shen, T., & Wang, X. (2021) · Life · doi:10.3390/life11080835 · Cited by 17
“As previous studies have shown that the abundance of T cell subsets, particularly that of tumor infiltrating T cells, could influence clinical curative effects and prognosis [60,61], our risk model has the potential to be applied for predicting the immunotherapy response.”
ResultWang, Z., Tian, Z., Song, X., & Zhang, J. (2022) · BMC Immunology · doi:10.1186/s12865-021-00475-z · Cited by 15
“Immoderate Tregs could keep the immune response from killing cancer cells and promote cancer progression [40].”
BackgroundBufe, S., Zimmermann, A., Ravens, S., Prinz, I., Buitrago‐Molina, L. E., Geffers, R., Woller, N., Kühnel, F., Talbot, S. R., Noyan, F., et al. (2022) · Liver Cancer · doi:10.1159/000526899 · Cited by 15
“Consequently, tumor remission was not due to depletion of Tregs by the anti-CTLA-4 antibody as described by others [28], but the expansion of effector T cells shifted the ratio of effectors to regulators in favor of a proinflammatory response.”
Dougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 17
Aoki, T., Kudo, M., Ueshima, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Tsurusaki, M., et al. (2023) · Liver Cancer · doi:10.1159/000531024 · Cited by 17
“Experiments using anti-CTLA-4 antibody without antibody-dependent cellular cytotoxicity activity have revealed the importance of depletion of effector Treg cells by anti-CTLA4 antibody from tumors to enhance antitumor immunity rather than direct activation of effector CD8+ T cells [51, 54, 55].”
David, P., Drabczyk-Pluta, M., Pastille, E., Knuschke, T., Werner, T., Honke, N., Megger, D. A., Akhmetzyanova, I., Shaabani, N., Eyking-Singer, A., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008340 · Cited by 17
“One obvious difference between our mouse data and the situation in human patients is that the anti-CTLA-4 antibody does only result in a partial depletion of Tregs in humans [29], whereas DT injection into DEREG mice results in a complete Treg depletion that lasts at least for several days.”
BackgroundInfluentialNahar, K. J., Marsh‐Wakefield, F., Rawson, R. V., Gide, T. N., Ferguson, A. L., Allen, R. O., Quek, C. Y. J., da Silva, I. P., Tattersall, S., Kiely, C. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157839 · Cited by 15
“Early studies showed a clear reduction in Tregs in blood and melanoma tumors after IPI (anti–CTLA-4) treatment (24, 29).”
BackgroundUpdate on Immunotherapy in Melanoma
Green, J. A., & Ariyan, C. E. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.12.010 · Cited by 15
On the Verge: Immunotherapy for Colorectal Carcinoma
Oh, D. Y., Venook, A. P., & Fong, L. H. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0117 · Cited by 16
The tumor microenvironment: Thousand obstacles for effector T cells
Massa, C., & Seliger, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.004 · Cited by 16
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies
Herzyk, D. J., & Haggerty, H. G. (2018) · The AAPS Journal · doi:10.1208/s12248-017-0184-3 · Cited by 15
“The BLT mouse, generated by surgical transplantation of human fetal liver and thymus tissue fragments into immune-deficient mice followed by intravenous injection of human fetal liver-derived CD34+ hematopoietic stem cell, expresses human FcRs similar to the levels expressed in humans (58).”
BackgroundInfluentialHofmann, S., Schmitt, M. W., Götz, M., Döhner, H., Wiesneth, M., Bunjes, D. W., & Greiner, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31753 · Cited by 16
“It might underline the hypothesis that the reduction of Treg could improve the efficacy of other immunotherapies like blinatumomab or checkpoint inhibitors.(45) These data are another encouraging observation for the combination of DLI with checkpoint inhibitors.”
BackgroundKim, N., Lee, D.-H., Choi, W. S., Yi, E., Kim, H., Kim, J. M., Jin, H., & Kim, H. S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.214 · Cited by 17
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
Hsu, M. M., & Balar, A. V. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.009 · Cited by 15
Clinical deployment of antibodies for treatment of melanoma
Curti, B. D., & Urba, W. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.025 · Cited by 15
Cancer evolution: Special focus on the immune aspect of cancer
Hu, X., Chen, Z., Wang, Z., & Xiao, Q. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.006 · Cited by 15
Regulation of T cell differentiation and function by long noncoding RNAs in homeostasis and cancer
Erber, J., & Herndler‐Brandstetter, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181499 · Cited by 16
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance
Bugno, J., Wang, L., Yu, X., Cao, X., Wang, J., Huang, X., Yang, K., Piffkó, A., Chen, K. S., Luo, S. Y., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3616 · Cited by 14
Afshari, A. R., Sanati, M., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216955 · Cited by 15
Smith, H., Arbe-Barnes, E. H., Abu‐Shah, E., & Sivakumar, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1406250 · Cited by 15
Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 19
“…the role of Fc effector function in the antitumor activity of mouse anti-CTLA-4 antibodies has been clearly demonstrated in mouse tumor models, 27–32, 37 its importance in patients is controversial, 34 especially because human anti-CTLA-4 anti-CTLA-4 anti-CTLA-4 antibodies antibodies fail to”
InfluentialSelf-citationCheckpoint inhibitors in H odgkin's lymphoma
Novaković, B. J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12697 · Cited by 15
New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer
van der Sluis, T. C., van der Burg, S. H., Arens, R., & Melief, C. J. M. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.05.002 · Cited by 17
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
A Review of T-Cell Related Therapy for Osteosarcoma
Yoshida, K., Okamoto, M., Aoki, K., Takahashi, J., & Saito, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144877 · Cited by 16
“By using an anti-CTLA4 antibody, the Treg expressing CTLA4 for their suppressive function were eliminated via antibody-dependent cellular cytotoxicity (ADCC) [72], and suppressed T-cells could be re-activated [73].”
MethodWu, Y., Yu, S., & Qiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990445 · Cited by 16
Morisada, M. V., Chamberlin, M. M., & Allen, C. T. (2018) · Head & Neck · doi:10.1002/hed.25101 · Cited by 15
Novel tumour antigens and the development of optimal vaccine design
Brentville, V. A., Atabani, S., Cook, K., & Durrant, L. G. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518768769 · Cited by 17
Promising vaccines for treating glioblastoma
Swartz, A. M., Shen, S. H., Salgado, M. A., Congdon, K. L., & Sanchez-Perez, L. A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1531846 · Cited by 14
Zhang, P., Xiong, X., Rolfo, C. D., Du, X., Zhang, Y., Yang, H., Russo, A., Devenport, M., Zhou, P., Liu, Y., et al. (2020) · Cancers · doi:10.3390/cancers12020284 · Cited by 15
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Saito, T., Kurose, K., Kojima, T., Funakoshi, T., Sato, E., Nishikawa, H., Nakajima, J., Seto, Y., Kakimi, K., Iida, S., et al. (2021) · PubMed · doi:10.18999/nagjms.83.4.827 · Cited by 24
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival
Fisher, S. A., Cleaver, A. L., Lakhiani, D. D., Khong, A., Connor, T., Wylie, B., Lesterhuis, W. J., Robinson, B. W. S., & Lake, R. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0245-7 · Cited by 15
“Recent studies have also shown that targeting the surface receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) on both effector and regulatory T cells, a process known as checkpoint blockade, can dramatically improve anti-tumor immunity [40–44], especially in advanced stage melanoma [45–47…”
BackgroundHuman regulatory T cells (Treg) and their response to cancer
Whiteside, T. L. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1634471 · Cited by 16
“Since anti-PD-1 antibodies induce death of at least some Treg through antibody-mediated cellular cytotoxicity (ADCC) [77], the overall effects of the PD-1 blockade may be the enhancement of Treg suppressive functions.”
BackgroundInfluentialA multi-omics analysis of effector and resting treg cells in pan-cancer
Chalepaki, A.-M., Gkoris, M., Chondrou, I., Kourti, M., Georgakopoulos‐Soares, I., & Zaravinos, A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110021 · Cited by 13
Regulatory T Cells in Tumor Microenvironment: Therapeutic Approaches and Clinical Implications
Sureka, N., & Zaheer, S. (2025) · Cell Biology International · doi:10.1002/cbin.70031 · Cited by 13
“These findings provide deeper insight into how anti ‐ CTLA ‐ 4 ‐ based immunotherapies function and underscore the significance of the tumor's local environment in determining therapeutic outcomes (Simpson et al. 2013).”
Ager, C. R., Obradović, A., McCann, P., Chaimowitz, M. G., Wang, A. L. E., Shaikh, N., Shah, P., Pan, S. S., Laplaca, C. J., Virk, R. K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102638 · Cited by 15
“20,32 If true, these findings would also support the hypothesis that first-generation anti-CTLA4 antibodies ipilimumab and tremelimumab may fail to deplete TI-Tregs in humans in part due to inefficient engagement of CD16a on TAMs, which has been proposed based on data from humanized murine models.”
Khurana, L., ElGindi, M., Tilstam, P. V., & Pantouris, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.053 · Cited by 16
Explant Modeling of the Immune Environment of Head and Neck Cancer
Sharon, S., Duhen, T. M., Bambina, S., Baird, J. R., Leidner, R. S., Bell, B., Casap, N., Crittenden, M. R., Vasudevan, S., Jubran, M. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.611365 · Cited by 14
“This may be particularly relevant for treatments such as anti-CTLA4, which has been proposed in preclinical models to function primarily as a Treg depleting therapy (50, 51).”
BackgroundZhao, Y., Xu, H., Zhang, M., & Li, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.881345 · Cited by 18
“…(by modulation of the Fc fraction or Fc receptor knockdown) showed that the anti-CTLA-4 mAb antitumor activity was attributed to depletion of FOXP3+CD4+ Treg cells from tumor tissue rather than direct activation of effector T cells (Bulliard et al., 2013; Selby et al., 2013; Simpson et al., 2013).”
BackgroundIshihara, M., Seo, N., Mitsui, J., Muraoka, D., Tanaka, M., Mineno, J., Ikeda, H., & Shiku, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104669 · Cited by 13
“Interestingly, it has been reported that an antiCTLA-4 antibody augments tumoricidal effector T cells by downregulation of Treg cell functions, including ADCC-mediated depletion of Treg cells [47], which is similar to our GITRtargeting results.”
ResultLindorfer, M. A., Beum, P. V., & Taylor, R. P. (2013) · Antibodies · doi:10.3390/antib2040598 · Cited by 13
“The mechanisms of action of monoclonal antibodies (mAbs) that have been approved for, or are under consideration to be used for the immunotherapy of cancer are under active and intense investigation [1–10].”
BackgroundDevelopment and Validation of a Functional Cell-Based Neutralizing Antibody Assay for Ipilimumab
Xu, W., Cummings, J., Sank, M., Juhel, M., Li, X., Gleason, C. R., Desilva, B. S., Dodge, R. W., & Pillutla, R. C. (2018) · Bioanalysis · doi:10.4155/bio-2018-0109 · Cited by 13
Turker, I., & Johnson, D. B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2254218 · Cited by 14
“Therefore, the net result in the tumor upon treatment with ipilimumab is an increased Teff/Treg ratio [15,16].”
BackgroundLAG ‐3—An incompletely understood target in cancer therapy
Leitner, J. M., Radakovics, K., & Steinberger, P. (2024) · The FASEB Journal · doi:10.1096/fj.202401639r · Cited by 12
Wolf, S., Madanchi, M., Turko, P., Hollmén, M., Tugues, S., von Atzigen, J., Giovanoli, P., Dummer, R., Lindenblatt, N., Halin, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55002-6 · Cited by 12
Zhou, Q., Yang, T., Yu, X., Li, B., Liu, J., Mao, Y., Guo, R., Feng, Z., Zhou, L., Zeng, G., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00200-y · Cited by 12
“Various antibodies are being used or evaluated to deplete Tregs, including those against CD25 (Shimizu et al, 1999), CTLA4 (Selby et al, 2013; Simpson et al, 2013), OX-40 (Bulliard et al, 2014), GITR (Bulliard et al, 2013), and CCR4 (Sugiyama et al, 2013).”
Amode, R., Baroudjian, B., Kowal, A., Jebali, M., Allayous, C., Bagot, M., Madjlessi, N., Roux, J., Viguier, M. A., Basset‐Séguin, N., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000313 · Cited by 12
Ono, S., Suzuki, S., Kondo, Y., Okubo, I., Goto, M., Ogawa, T., Kato, H., Ito, H., Takahara, T., Satou, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22773-1 · Cited by 14
“Ipilimumab, an anti-CTLA-4 mAb known to function as an immune checkpoint inhibitor, also induces ADCC in Tregs 29–31 .”
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Lee, K., Kim, H., & Yoon, S. Y. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.060 · Cited by 12
“(3) The anti-CTLA-4 antibody downregulates regulatory T-cells (Treg), leading to immune revitalization and attack of normal selfcells [22-24].”
BackgroundQian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 13
“The response to anti-CTLA-4 treatment was related to the ratio of Teff to Tregs, and the higher the ratio, the better the response to treatment.([92,93]) A retrospective study reported that the high expression of FoxP3+ Tregs was associated with better prognosis in patients treated with anti-CTLA-4 therapy.”
BackgroundMethods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies
Allard, B., Allard, D., & Stagg, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3801-8_12 · Cited by 12
Murer, P., Kiefer, J. D., Plüss, L., Matasci, M., Blümich, S., Stringhini, M., & Neri, D. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.028 · Cited by 12
“ADCC may even play a role in the growing field of immune checkpoint inhibitors (Arce Vargas et al., 2018; Ingram et al., 2018; Simpson et al., 2013).”
BackgroundJoshi, K., Chain, B., Peggs, K. S., & Quezada, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027086 · Cited by 14
“Further evaluation of mechanism of action has suggested that the antibodies can act both by blocking inhibitory signaling on effector T cells and by driving Fcg receptor-mediated depletion of tumor infiltrating regulatory T cells expressing higher levels of CTLA-4 than effector T cells (Quezada et al. 2006, 2008; Pegg…”
BackgroundSelf-citationPichon, S., Aigrain, P., Lacombe, C., Lemarchant, B., Ledoult, E., Koether, V., Leurs, A., Zebian, G., Launay, D., Gachet, B., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12660-2 · Cited by 11
“In animal models, anti-CTLA4 drugs induce major depletion of regulatory T cells, and mouse model of anti-PD-1 deletion resulted in lupus-like proliferative arthritis and glomerulonephritis [109, 110].”
Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance
Mei, T., Ye, T., Huang, D., Xie, Y., Xue, Y., Zhou, D., Wang, W., & Chen, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01009-6 · Cited by 12
Vitale, M., Pagliaro, R., Viscardi, G., Pastore, L., Castaldo, G., Perrotta, F., Campbell, S. F. M., Bianco, A., & Scialò, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189244 · Cited by 12
“The ratio between Teff and Tregs is closely related to ICI responses, and the factors that stimulate Treg proliferation are presumptive biomarkers of resistance with a poor prognosis [68,69].”
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.